Insmed Incorporated (NASDAQ:INSM) CEO William Lewis Sells 18,750 Shares of Stock

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 18,750 shares of the firm’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $77.79, for a total value of $1,458,562.50. Following the completion of the sale, the chief executive officer now directly owns 334,186 shares in the company, valued at approximately $25,996,328.94. The trade was a 5.31 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

William Lewis also recently made the following trade(s):

• On Tuesday, February 18th, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $81.03, for a total transaction of $1,519,312.50.
• On Thursday, February 6th, William Lewis sold 79,350 shares of Insmed stock. The shares were sold at an average price of $80.90, for a total transaction of $6,419,415.00.
• On Monday, February 3rd, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $77.94, for a total transaction of $1,461,375.00.
• On Wednesday, January 15th, William Lewis sold 31,805 shares of Insmed stock. The shares were sold at an average price of $70.18, for a total transaction of $2,232,074.90.
• On Friday, January 10th, William Lewis sold 2,978 shares of Insmed stock. The stock was sold at an average price of $63.36, for a total transaction of $188,686.08.
• On Tuesday, January 7th, William Lewis sold 8,218 shares of Insmed stock. The shares were sold at an average price of $66.02, for a total value of $542,552.36.
• On Thursday, January 2nd, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $69.84, for a total value of $1,309,500.00.
• On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $69.91, for a total value of $1,310,812.50.

Insmed Price Performance

INSM opened at $77.55 on Thursday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The stock has a market capitalization of $14.04 billion, a PE ratio of -13.87 and a beta of 1.11. The stock’s 50 day moving average price is $75.46 and its 200-day moving average price is $73.84. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $84.91.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The company had revenue of $104.44 million for the quarter, compared to analysts’ expectations of $102.31 million. On average, equities research analysts predict that Insmed Incorporated will post -4.56 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on INSM shares. Royal Bank of Canada assumed coverage on shares of Insmed in a research report on Tuesday, February 25th. They set an “outperform” rating and a $100.00 price target on the stock. Guggenheim reaffirmed a “buy” rating and set a $101.00 target price on shares of Insmed in a report on Tuesday, February 25th. HC Wainwright reissued a “buy” rating and issued a $90.00 price target on shares of Insmed in a research note on Friday, February 21st. Wells Fargo & Company raised their price objective on Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research note on Wednesday, February 19th. Finally, Morgan Stanley lifted their price objective on Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 6th. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $91.60.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Elequin Capital LP bought a new stake in shares of Insmed during the 4th quarter valued at $28,000. Steward Partners Investment Advisory LLC lifted its holdings in shares of Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 163 shares during the last quarter. V Square Quantitative Management LLC boosted its position in shares of Insmed by 60.3% in the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 248 shares in the last quarter. Spire Wealth Management purchased a new stake in shares of Insmed in the 4th quarter worth approximately $47,000. Finally, Smartleaf Asset Management LLC increased its position in Insmed by 98.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 411 shares in the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.